Smith & Nephew SNATS Inc Stock News

The list ranks stocks based on their market cap and dividend yield alone. What I am looking for is quality dividend stocks with long track records of progressive dividend growth, and while dividend yi

The latest partnership allows Smith+Nephew (SNN) to complement its existing implant range with the cutting-edge navigation technology of NAVBIT.

There are some robotic surgery stocks for investors to buy in March this year. The growth of robotic-assisted surgery has been driven by its potential benefits, such as smaller incisions, reduced pain

JP Morgan has spotlighted Smith & Nephew PLC (LSE:SN) for its revenue acceleration and margin expansion potential, setting a price target of 1,300p - a 21% premium to the current stock price. Despite

Smith & Nephew plc (SNN) Q4 2023 Earnings Call Transcript

Smith & Nephew PLC (LSE:SN) kept its dividend unchanged and guided to solid growth this year as it reported 2023 results in line with improved guidance from last summer. The hip and knee replacement s

There are some key robotics stocks for investors to buy in February. This is amid the broader indices such as the Nasdaq making a brief pullback.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest

Smith & Nephew PLC (LSE:SN) said today that it has closed the acquisition of CartiHeal, an Israel-based developer of sports medicine technology for cartilage regeneration in the knee.  The medical

Smith & Nephew shares are down 3.6% since February, but management has increased top-line growth guidance for fiscal 2022. The Orthopedics business unit is showing strong growth potential, with moment

Smith & Nephew (SNN) will pay an initial cash consideration of $180 million at closure, with an additional $150 million based on financial performance to acquire CartiHeal.

Smith & Nephew PLC (LSE:SN) has announced the acquisition of knee cartilage regeneration technology developer CartiHeal. Under the agreement, the FTSE 100-listed medical equipment manufacturer will p

Smith & Nephew PLC (LSE:SN)'s underperformance is set to change, according to Goldman Sachs (NYSE:GS). The investment bank has initiated coverage of the medical technology outfit with a buy rating and

For weeks, I have pounded the table about the historic opportunity in REITs. The fundamentals were clear that now was the best time in 14 years to buy REITs. Last week, stocks ripped 6% higher, and RE